Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans

The mitogen-activated protein kinase (MEK) inhibitor zapnometinib is in development to treat acute viral infections like COVID-19 and influenza. While the antiviral efficacy of zapnometinib is well documented, further data on target engagement/pharmacodynamics (PD) and pharmacokinetics (PK) are need...

Descripción completa

Detalles Bibliográficos
Autores principales: Koch-Heier, Julia, Schönsiegel, Annika, Waidele, Lara Maria, Volk, Julian, Füll, Yvonne, Wallasch, Christian, Canisius, Sebastian, Burnet, Michael, Planz, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240354/
https://www.ncbi.nlm.nih.gov/pubmed/35784712
http://dx.doi.org/10.3389/fphar.2022.893635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240354/
https://www.ncbi.nlm.nih.gov/pubmed/35784712
http://dx.doi.org/10.3389/fphar.2022.893635

Ejemplares similares